文献速递乳腺癌放疗

加速部分乳腺照射与全乳照射的毒性和美容效果比较

Comparison of Toxicity and Cosmetic Outcomes After Accelerated Partial Breast Irradiation or Whole Breast Irradiation Using 3-Dimensional Conformal External Beam Radiation Therapy.
PubMed 文献 · Adv Radiat Oncol · 2019-09-27

本研究纳入133例保乳术后乳腺癌患者,随机接受三维适形加速部分乳腺照射(APBI,34 Gy/10次/5天)或全乳照射(WBI,40 Gy/16次/3周±补量)。中位随访60个月,APBI组晚期≥1级乳腺萎缩、色素沉着、纤维化、硬结发生率更低,不良美容结局显著更少(6%对33%,P<.001),≥2级急性皮炎两组无显著差异。

要点

  • APBI组不良美容结局6%,显著低于WBI组33%(P<.001)。
  • APBI组晚期≥1级乳腺萎缩、色素沉着、纤维化、硬结发生率均显著低于WBI组。
  • 两组均未出现4级晚期毒性,3级毒性各终点均很低。

核心结论

  • 保乳术后乳腺癌患者中,APBI相比WBI与更好的美容结局和更少的晚期放疗毒性相关。

研究设计与样本

  • 随机对照试验,2011年6月至2015年12月纳入133例>35岁、≤4 cm的浸润性或非浸润性乳腺癌保乳术后患者,随机分配至3D-CRT APBI或WBI。

主要发现

  • 中位随访60个月(范围12-93个月),两组患者和肿瘤特征均衡。
  • ≥2级急性皮炎发生率APBI组8%、WBI组15%(P=.18)。
  • 晚期≥1级毒性WBI组高于APBI组:乳腺萎缩(P=.008)、色素沉着(P=.028)、纤维化(P=.040)、硬结(P=.048)、水肿(P=.33)。
  • 末次随访不良美容结局WBI组33%、APBI组6%(P<.001)。
  • 两组均未观察到4级晚期毒性,各评估终点的3级毒性均很低。

关键数值与推荐

  • APBI方案:34 Gy分10次、5天;WBI方案:40 Gy分16次、3周±补量照射。
  • 急性皮炎按RTOG评分,晚期毒性采用LENT-SOMA量表,不良美容结局为次要终点。

临床怎么用

  • 对于符合条件的保乳术后乳腺癌患者,3D-CRT APBI可减少晚期放疗毒性并改善美容结局。

局限性

  • 本文为中期分析,聚焦毒性和美容次要终点,主要终点同侧乳腺肿瘤复发结果未报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare rates of acute and late skin toxicities and cosmetic outcomes after accelerated partial breast irradiation (APBI) or whole breast irradiation (WBI) using 3-dimensional conformal external beam radiation therapy in women with breast cancer after breast conservation surgery (BCS). METHODS AND MATERIALS: Women >35 years of age with invasive or noninvasive breast cancer ≤4 cm treated by BCS were randomized to 3D-CRT APBI (34 Gy/10 fractions/5 days) or WBI (40 Gy/16 fractions/3 weeks ± boost irradiation). The primary outcome was ipsilateral breast tumor recurrence. Important secondary outcomes were skin toxicities using Radiation Therapy Oncology Group scores, Late Effects Normal Tissue Task Force and Subjective, Objective, Management, Analytic scales, and adverse cosmetic outcome. This interim analysis focuses on the secondary endpoints of radiation toxicities and cosmesis. Patient and tumor characteristics and rates of adverse cosmetic outcomes and skin toxicities were compared using Fisher exact tests. All statistical tests were 2 sided, with P < .05 considered statistically significant. RESULTS: Between June 2011 and December 2015, 133 women with breast cancer were randomized to 3D-CRT APBI or WBI. Patient and tumor characteristics were balanced between the 2 arms. Median follow-up was 60 months (range, 12-93 months). Grade 4 late toxicity was not seen in either of the treatment arms, and grade 3 toxicity was very low for each endpoint assessed in both the groups. The rates of grade ≥2 acute dermatitis were 8% and 15%, respectively, for APBI and WBI (P = .18). Rates of grade ≥1 late radiation toxicities were higher in the WBI arm compared with the APBI arm for breast shrinkage (P = .008), pigmentation (P = .028), fibrosis (P = .040), induration (P = .048), and edema (P = .33). Adverse cosmesis at last follow-up was significantly higher in patients treated with WBI: 33% compared with 6% with APBI (P < .001). CONCLUSIONS: In women with breast cancer after BCS, APBI was associated with better cosmetic outcome and fewer late radiation toxicities than WBI.

来源:Adv Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yadav BS, Loganathan S, Sharma SC, et al. Comparison of Toxicity and Cosmetic Outcomes After Accelerated Partial Breast Irradiation or Whole Breast Irradiation Using 3-Dimensional Conformal External Beam Radiation Therapy. Adv Radiat Oncol. 2019. PMID: 32280816. doi:10.1016/j.adro.2019.09.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。